Fifth Third Bancorp reports 299.40% increase in ownership of 1VRTX / Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

IT ˙ BIT ˙ US92532F1003

366,30 € ↓ -1,30 (-0,35%)

2026-06-03
AKTIENPREIS

Security	IT:1VRTX / Vertex Pharmaceuticals Incorporated
Institution	Fifth Third Bancorp
Latest Disclosed Ownership	88,499 shares
Latest Disclosed Value	$ 39,518,627

On May 1, 2026 - Fifth Third Bancorp filed a 13F-HR form disclosing ownership of 88,499 shares of Vertex Pharmaceuticals Incorporated (IT:1VRTX) valued at $33,594,220 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 22,158 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 299.40% during the quarter. The current value of the position is $32,417,184 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-01	2026-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	88,499	66,341	299.40	39,519	293.41	0.0722
2026-02-02	2025-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	22,158	-65	-0.29	10,046	15.42	0.0319
2025-11-07	2025-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	22,223	-2,001	-8.26	8,703	-19.30	0.0278
2025-07-15	2025-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	24,224	-1,585	-6.14	10,785	-13.81	0.0373
2025-04-15	2025-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	25,809	-294	-1.13	12,513	19.04	0.0476
2025-01-21	2024-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	26,103	-937	-3.47	10,512	-16.41	0.0381
2024-10-17	2024-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	27,040	418	1.57	12,576	0.78	0.0456
2024-07-22	2024-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	26,622	-119	-0.45	12,478	11.63	0.0475
2024-04-23	2024-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	26,741	-316	-1.17	11,178	1.54	0.0437
2024-01-19	2023-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	27,057	-478	-1.74	11,009	14.98	0.0468
2023-10-31	2023-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	27,535	60	0.22	9,575	-0.96	0.0444
2023-07-26	2023-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	27,475	-1,579	-5.43	9,669	5.62	0.0427
2023-04-24	2023-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	29,054	2,580	9.75	9,154	19.74	0.0426
2023-01-25	2022-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	26,474	1,387	5.53	7,645	5.25	0.0367
2022-10-25	2022-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	25,087	2,716	12.14	7,264	15.23	0.0380
2022-08-04	2022-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	22,371	2,401	12.02	6,304	20.95	0.0305
2022-04-19	2022-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	19,970	4,047	25.42	5,212	49.04	0.0213
2022-02-01	2021-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	15,923	-1,130	-6.63	3,497	13.06	0.0136
2021-10-15	2021-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	17,053	-4,899	-22.32	3,093	-30.12	0.0134
2021-08-06	2021-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	21,952	-54,768	-71.39	4,426	-73.15	0.0194
2021-05-07	2021-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	76,720	-9,848	-11.38	16,486	-19.42	0.0765
2021-02-16	2020-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	86,568	30,612	54.71	20,459	34.36	0.1006
2020-11-09	2020-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	55,956	15,863	39.57	15,227	30.83	0.0841
2020-08-05	2020-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	40,093	34,496	616.33	11,639	773.80	0.0698
2020-05-05	2020-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	5,597	95	1.73	1,332	10.54	0.0095
2020-02-14	2019-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	5,502	188	3.54	1,205	33.89	0.0067
2019-11-14	2019-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	5,314	-927	-14.85	900	-21.33	0.0054
2019-08-07	2019-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	6,241	30	0.48	1,144	0.09	0.0070
2019-05-14	2019-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	6,211	1,058	20.53	1,143	33.84	0.0073
2019-02-14	2018-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	5,153	55	1.08	854	-13.12	0.0062
2018-11-14	2018-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	5,098	243	5.01	983	19.15	0.0063
2018-08-14	2018-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	4,855	266	5.80	825	10.29	0.0056
2018-05-15	2018-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	4,589	4,115	868.14	748	953.52	0.0051
2018-02-14	2017-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	474	77	19.40	71	18.33	0.0005
2017-11-14	2017-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	397	123	44.89	60	71.43	0.0004
2017-08-11	2017-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	274	33	13.69	35	34.62	0.0003
2017-05-12	2017-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	241	11	4.78	26	52.94	0.0002
2017-02-13	2016-12-31	13F/A-1	VERTEX PHARMACEUTICALS	COM	92532F100	230	-212	-47.96	17	-56.41	0.0001
2017-02-09	2016-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	442	0		39		0.0003
2016-11-10	2016-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	442	-142	-24.32	39	-22.00	0.0003
2016-08-11	2016-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	584	-483	-45.27	50	-41.18	0.0004
2016-05-13	2016-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	1,067	-1,025	-49.00	85	-67.68	0.0007
2016-02-16	2015-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,092	215	11.45	263	34.87	0.0023
2015-11-13	2015-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	1,877	-326	-14.80	195	-28.31	0.0018
2015-08-14	2015-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	2,203	773	54.06	272	60.95	0.0024
2015-05-14	2015-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	1,430	352	32.65	169	32.03	0.0015
2015-02-13	2014-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	1,078	98	10.00	128	16.36	0.0011
2014-11-17	2014-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	980	118	13.69	110	34.15	0.0010
2014-08-14	2014-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	862	24	2.86	82	38.98	0.0007
2014-05-15	2014-03-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	838	-87	-9.41	59	-14.49	0.0006
2014-02-14	2013-12-31	13F	VERTEX PHARMACEUTICALS	COM	92532F100	925	362	64.30	69	60.47	0.0007
2013-11-14	2013-09-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	563	-228	-28.82	43	-31.75	0.0004
2013-08-14	2013-06-30	13F	VERTEX PHARMACEUTICALS	COM	92532F100	791	791		63		0.0007

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.